


## Webcast Agenda.

27. MAY

SESSION A | 12:00 - 14:00 CET

We would like to invite you to our webcast, the 10 Years of Simplicity, Join us for this 2-hour, interactive webcast to discuss Trajenta® and how 10 years of experience have helped simplify the management of type 2 diabetes for physicians and patients worldwide. Hear perspectives from leading international experts in the treatment of type 2 diabetes. See the detailed agenda below.



(1) 12:00 - 12:05

#### Welcome to 10 Years of Trajenta®

Professor Per Henrik Groop and Dr Sarah Jarvis

Webcast objectives and introduction of Chair

12:05 - 12:35

### 10 Years of Improvement in T2D Patient Care

Professor Clifford J. Bailey

- Chair to introduce faculty
- Paradigm shift in T2D guidelines based on evidence of proven CV benefit
- The role of DPP4i in treatment of T2D and the evolution of the Trajenta® profile (proven efficacy,¹ convenience, followed by CV and kidney safety from CVOTs)

12:35 - 12:55

# CARMELINA® and CAROLINA®: An Extensive Dataset From A Unique CVOT Programme

Professor Nikolaus Marx

- Robust CV and kidney safety data from CARMELINA® and CAROLINA® in patients across a broad spectrum of T2D disease duration, CV and kidney risk
- Trajenta® is the only DPP4i with 2 large CVOTs, including an active-comparator trial

**12:55 - 13:15** 

# Can A Broad Range of T2D Patients Benefit From The Simplicity of Linagliptin?

Professor Per-Henrik Groop

- Proven efficacy¹ for a broad range of patients, and convenience of always one dose, once daily
- Data from CARMELINA® and CAROLINA® subgroup analyses support CV and kidney safety profile of Trajenta® and continue to generate scientific evidence from the CVOT programme

13:15 - 13:35

### Defining Simplicity in Clinical Practice – A Case-Driven Approach

Dr Sarah Jarvis

- Patient cases incorporating speaker experience with Trajenta®
- Data from Trajenta® CVOTs support treatment decision making

**(**) 13:35 - 13:45

### Summarising The Advances That Linagliptin Has Brought to T2D Care

Professor Per-Henrik Groop

- Vast experience with Trajenta®
- Highlights of Trajenta® simplicity (efficacy, safety, convenience)

**(**) 13:45 - 14:00

#### **Q&A** and Close

Professor Per-Henrik Groop and Dr Sarah Jarvis

- Audience Q&A
- Moderator to reinforce the simplicity of Trajenta® and close the webcast

1. Trajenta® EMA Summary of Product Characteristics. October 2019.







